Goldman Sachs Reports A 5.9% Passive Stake In Tandem Diabetes Care
The insulin-pump company is shifting customers toward pharmacies while preparing for a change in leadership.
Goldman Sachs reported a 5.9% passive stake in Tandem Diabetes Care, which sells insulin pumps and related software, in an SEC ownership disclosure filed Monday. The position dates to September 30, 2026, and Goldman certified that the securities were held for ordinary business purposes, rather than to influence control.
Goldman's Position Predates The Slide
The Goldman Sachs Group and Goldman Sachs & Co. LLC each reported the same 4,091,935.35-share position. Those figures describe the reported holding, rather than separate stakes to be added together. Each also reported shared voting power over 4,082,859.35 shares.
The ownership calculation includes securities acquirable within 60 days in both the holding and the common-stock share base.
Tandem shares fell about 12% in the week preceding Monday's disclosure. The company had a market value of $1.2 billion as of Monday's original report.
Growing Sales, Slower Pharmacy Adoption
Tandem's third-quarter revenue rose 14% to $284 million. Worldwide pump shipments reached approximately 33,000, up 12%.
Customers use Tandem's t:slim X2 and Tandem Mobi pumps with continuous glucose monitoring sensors. Its Control-IQ+ algorithm automatically adjusts insulin dosing, and the company also sells replacement cartridges and infusion sets. Its annual-report profile describes a business serving nearly 500,000 people across more than 25 countries.
Chief financial officer Leigh Vosseller said pharmacy adoption had progressed more slowly than originally anticipated, partly because prescribing workflows needed time to develop. PayGo lets customers obtain pumps without an upfront payment; recurring purchases of supplies offset the initial revenue shortfall over time.
Vosseller said Tandem expects to shift almost entirely to pharmacies from durable medical equipment distribution by the end of 2028.
Incoming president and CEO Jeannette Bankes is set to join Tandem next Monday. Current president and CEO John Sheridan is preparing to retire at the end of 2026.
Sources
- SCHEDULE 13G — THE GOLDMAN SACHS GROUP, INC. re: TANDEM DIABETES CARE, INC. (TNDM) — SEC EDGAR
- Can Tandem Diabetes Care (TNDM) Justify Its Valuation As Q3 Earnings Beat And CEO Change Land? — Yahoo Finance
- What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call — Yahoo Finance
- Tandem Earnings: Solid Third-Quarter Performance Is Backdrop for Major Management Change | Morningstar — morningstar.com
- Tandem (TNDM) Q3 2026 Earnings Call Transcript — Yahoo Finance
- Tandem outlines $1.065B-$1.085B 2026 sales range as CEO transition set for end of 2026 (NASDAQ:TNDM) | Seeking Alpha — seekingalpha.com
